Unstable angina
Unstable angina is chest pain or discomfort from too little blood flow to the heart that follows no regular pattern. It can come without physical effort and does not go away with rest or medicine. A US government patient page calls it the most dangerous type of angina and a sign that a heart attack could come soon. MeSH describes it as pain at rest that may come before a heart attack.
- Condition
- In this atlas
Overview
Technical summary
MeSH D000789, last updated 2017-06-20; the description of pain at rest comes from its scope note. The patient page is the MedlinePlus angina summary. The place under acute coronary syndrome rests on the first sentence of the abstract of one open-access paper (PMC11904130).
Recognition
A US government patient page says angina may feel like pressure or a squeezing pain in the chest, may feel like indigestion, and may also be felt in the shoulders, arms, neck, jaw or back.
Burden
No burden claims are published.
Claims and evidence
No claims are published for this condition yet.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact Evaluated for this: Prasugrel
Applies to Recipient not specified People for whom the US label of prasugrel (Effient) lists an indication: acute coronary syndrome managed with percutaneous coronary intervention
Population, setting and follow-up
- Patients described in the indications section of the label. The label passages read do not state an age range.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Not stated in the label passages read
- Gestational age Not reported
- Postnatal age Not reported
The US label of Effient (prasugrel), in the Cosette Pharmaceuticals, Inc. version dated 2022-09-07 in openFDA, lists the medicine to reduce the rate of thrombotic cardiovascular events, including stent thrombosis, in patients with acute coronary syndrome who are to be managed with percutaneous coronary intervention (PCI): patients with unstable angina or non-ST-elevation myocardial infarction, and patients with ST-elevation myocardial infarction managed with primary or delayed PCI. The label carries a boxed warning that the medicine can cause significant, sometimes fatal, bleeding.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the indications, the first line of the boxed warning and the mechanism sentence were read; the rest of the boxed warning, contraindications, doses, interactions and other warnings were not recorded. Labels change, and openFDA's version may be older than the current label. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact Evaluated for this: Verapamil
Applies to Recipient not specified People for whom the US label of verapamil hydrochloride tablets lists an indication: angina, atrial flutter or fibrillation, supraventricular tachycardia, hypertension
Population, setting and follow-up
- Patients described in the indications section of the label. The label does not state an age range in the passages read.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Not stated in the label passages read
- Gestational age Not reported
- Postnatal age Not reported
The US label of verapamil hydrochloride tablets, in the Actavis Pharma, Inc. version dated 2024-01-30 in openFDA, lists the medicine for angina (angina at rest, including vasospastic and unstable angina, and chronic stable angina); for arrhythmias (control of ventricular rate at rest and during stress, in association with digitalis, in patients with chronic atrial flutter or atrial fibrillation, and prophylaxis of repetitive paroxysmal supraventricular tachycardia); and for the treatment of hypertension, to lower blood pressure.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry trials 60
Record details
- Record id
cardio:unstable-angina- Content hash
f9ff8a322a3f2ebf9320a23cda8ad123fd55e93f8113f339f962d2e5727bab71